Next Article in Journal
Theranostic Value of Multimers: Lessons Learned from Trimerization of Neurotensin Receptor Ligands and Other Targeting Vectors
Next Article in Special Issue
Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
Previous Article in Journal
Protein Kinase CK2: Intricate Relationships within Regulatory Cellular Networks
Previous Article in Special Issue
Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future
Open AccessReview

Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma

by Fengting Yan 1,2, Ajay K. Gopal 1,2 and Solomon A. Graf 1,2,3,*
1
Department of Medicine, University of Washington, Seattle, WA 98195, USA
2
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
3
Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Luciano J. Costa
Pharmaceuticals 2017, 10(1), 28; https://doi.org/10.3390/ph10010028
Received: 27 January 2017 / Revised: 6 March 2017 / Accepted: 8 March 2017 / Published: 10 March 2017
(This article belongs to the Special Issue New Drugs in Hematology)
The treatment landscape for mantle cell lymphoma (MCL) is rapidly evolving toward the incorporation of novel and biologically targeted pharmaceuticals with improved disease activity and gentler toxicity profiles compared with conventional chemotherapeutics. Upfront intensive treatment of MCL includes autologous stem cell transplantation (SCT) consolidation aimed at deepening and lengthening disease remission, but subsequent relapse occurs. Maintenance therapy after autologous SCT in patients with MCL in remission features lower-intensity treatments given over extended periods to improve disease outcomes. Targeted drugs are a natural fit for this space, and are the focus of considerable clinical investigation. This review summarizes recent advances in the field and their potential impact on treatment practices for MCL. View Full-Text
Keywords: stem cell transplantation; mantle cell lymphoma; maintenance therapy stem cell transplantation; mantle cell lymphoma; maintenance therapy
MDPI and ACS Style

Yan, F.; Gopal, A.K.; Graf, S.A. Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma. Pharmaceuticals 2017, 10, 28.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop